期刊
METABOLISM-CLINICAL AND EXPERIMENTAL
卷 126, 期 -, 页码 -出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2021.154918
关键词
SGLT2 inhibitors; Cardiovascular disease; Heart failure; Chronic kidney disease; Diabetes; Biomarkers
资金
- Department of Medicine, University of Toronto
- CIHR
- Diabetes Canada
- Heart and Stroke Richard Lewar Centre of Excellence
- Canadian Institutes for Health Research
- Thistledown Foundation
- Peter Munk Cardiac Centre
- LifeArc Foundation
- Province of Ontario
- Ted Rogers Centre for Heart Research
- Department of Medicine Eliot Phillipson Clinician Scientist Training Program
- Banting and Best Diabetes Centre Postdoctoral fellowship at the University of Toronto
- CIHR Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award
- FRQS Masters award
SGLT2 inhibitors have emerged as an effective treatment for cardiovascular and renal diseases associated with T2D, with diverse benefits. Research is underway to elucidate the mechanisms underlying the effects of SGLT2 inhibitors.
Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease (CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the cornerstones for preventing progression of CKD and CV disease associated with T2D. However, there has been a paradigm shift in treatment since the publication of the first clinical trial demonstrating benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors in 2015. SGLT2 inhibitors have been shown to reduce the risk of major adverse CV events and progression of kidney disease in the setting of T2D. However, the elucidation of mechanisms of underlying these clinical benefits is the subject of ongoing investigation. Experimental studies have shown that SGLT2 inhibitors have diverse pleiotropic effects such as modulation of neurohormones such as the renin-angiotensin-aldosterone system, increasing hematocrit, altering energy substrate use, and attenuating systemic inflammation and oxidative stress, all of which have been implicated in the CV and kidney protective effects of SGLT2 inhibitors. In this review, we highlight biomarkers linked with diabetic kidney disease and heart failure and discuss how SGLT2 inhibitor-associated changes potentially mediate the cardiorenal protection observed with these therapies. (c) 2021 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据